|SM-276001 is a selective and potent TLR7 agonist. SM-276001 is can induce antitumor immune responses when dosed either intratracheally or orally. Oral administration of SM-276001 leads to the induction of IFNα, TNFα and IL-12p40 and a reduction in tumor burden in the Balb/c syngeneic Renca and CT26 models.
|GSK2245035 is a selective Toll-like receptor 7 (TLR7) agonist with preferential Type-1 interferon (IFN)-stimulating properties. GSK2245035 displays extraordinary IFNα inducing potency and IFNα/TNFα selectivity. GSK2245035 shows excellent pharmaceutical properties that allow reliable delivery of doses as low as 1 ng per actuation of an intranasal spray formulation. Intranasal GSK2245035 has an acceptable safety profile at doses that induce local TLR7-mediated immune responses.